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Background: Nitric oxide (NO), generated in skeletal muscle mostly by the neuronal NO synthases (nNOSμ), has
profound effects on both mitochondrial bioenergetics and muscle development and function. The importance of
NO for muscle repair emerges from the observation that nNOS signalling is defective in many genetically diverse
skeletal muscle diseases in which muscle repair is dysregulated. How the effects of NO/nNOSμ on mitochondria
impact on muscle function, however, has not been investigated yet.
Methods: In this study we have examined the relationship between the NO system, mitochondrial structure/activity
and skeletal muscle phenotype/growth/functions using a mouse model in which nNOSμ is absent. Also, NO-induced
effects and the NO pathway were dissected in myogenic precursor cells.
Results: We show that nNOSμ deficiency in mouse skeletal muscle leads to altered mitochondrial bioenergetics and
network remodelling, and increased mitochondrial unfolded protein response (UPRmt) and autophagy. The absence of
nNOSμ is also accompanied by an altered mitochondrial homeostasis in myogenic precursor cells with a decrease in
the number of myonuclei per fibre and impaired muscle development at early stages of perinatal growth. No
alterations were observed, however, in the overall resting muscle structure, apart from a reduced specific muscle mass
and cross sectional areas of the myofibres. Investigating the molecular mechanisms we found that nNOSμ deficiency
was associated with an inhibition of the Akt-mammalian target of rapamycin pathway. Concomitantly, the Akt-FoxO3-
mitochondrial E3 ubiquitin protein ligase 1 (Mul-1) axis was also dysregulated. In particular, inhibition of nNOS/NO/cyclic
guanosine monophosphate (cGMP)/cGMP-dependent-protein kinases induced the transcriptional activity of FoxO3 and
increased Mul-1 expression. nNOSμ deficiency was also accompanied by functional changes in muscle with reduced
muscle force, decreased resistance to fatigue and increased degeneration/damage post-exercise.
Conclusions: Our results indicate that nNOSμ/NO is required to regulate key homeostatic mechanisms in skeletal
muscle, namely mitochondrial bioenergetics and network remodelling, UPRmt and autophagy. These events are likely
associated with nNOSμ-dependent impairments of muscle fibre growth resulting in a deficit of muscle performance.
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Nitric oxide (NO) is a gas and a messenger with pleio-
tropic functions in most tissues and organs, synthesized
by a family of NO synthases. NO is also generated in
skeletal muscle, in particular by the muscle-specific
neuronal NO synthases (nNOS or NOS1) [1,2]. nNOSμ
is the predominant nNOS isoform in muscle and is an-
chored to the sarcolemma as a component of the dys-
trophin glycoprotein complex [3]. This enzyme produces
NO at low, physiological levels (in the pico to nanomolar
range) in a way controlled by second messengers [1,2];
its expression is increased by crush injury, muscle activ-
ity and ageing [4,5]. NO has an important role in regu-
lating skeletal muscle physiological activity, including
excitation-contraction coupling, muscle force generation,
auto-regulation of blood flow, calcium homeostasis, me-
tabolism and bioenergetics [2,6,7]. In addition, it is a key
determinant in myogenesis that it regulates at several
key steps, especially when the process is stimulated to
repair muscle damage after injury [5,8,9].
The importance of NO in muscle repair also emerges
from the observation that nNOS signalling is defective in
many genetically diverse skeletal muscle diseases in which
muscle repair is dysregulated, including Duchenne muscu-
lar dystrophy, Becker muscular dystrophy, limb-girdle
muscular dystrophies 2C, 2D and 2E, Ullrich congenital
muscular dystrophy and inflammatory myositis [3,10-13].
Based on this evidence and on the fact that the restoration
of NO signalling by nNOS overexpression ameliorates
muscle function [14,15], genetic and pharmacologic strat-
egies to boost nNOS/NO signalling in dystrophic muscle
are being tested with encouraging results: in particular, the
combination of NO donation with non steroidal anti-
inflammatory activity limits muscle damage and favours
muscle healing in vivo [16-18] such that it is currently be-
ing tested as a therapeutic for Duchenne muscular dys-
trophy in humans [19,20].
The observation that nNOS is localised in close prox-
imity to mitochondria suggests a tight coupling between
NO generation and regulation of mitochondrial respir-
ation and metabolism. The role of NO in regulating oxi-
dative phosphorylation and mitochondrial biogenesis in
skeletal muscle physiology has been established [21-24].
Likewise NO-dependent inhibition of mitochondrial fis-
sion occurs during myogenic differentiation [25].
How the effects of NO on mitochondria impact on
muscle function, however, has not been investigated yet.
Elucidation of this aspect is relevant in view of the role
that mitochondria play in muscle pathophysiology and
may shed light on the muscular disorders in which NO
signalling is impaired [26]. In particular, increases in
mitochondria number and oxidative phosphorylation ac-
tivity is relevant during differentiation [27] and the bal-
ance of fission and fusion is necessary to preserveexcitation contraction coupling and prevent atrophy
[28,29]. In addition, mitochondria are involved in regulat-
ing autophagy [30], whose derangement plays a role in a
number of inherited muscle diseases [31-33]. Mitochon-
drial protein homeostasis is maintained through proper
folding and assembly of polypeptides. This involves the
mitochondrial unfolded protein response (UPRmt), a stress
response that activates transcription of nuclear-encoded
mitochondrial chaperone genes to maintain proteins in a
folding or assembly-competent state, preventing deleteri-
ous protein aggregation [34-36].
In this study we have examined the relationship between
the NO system, mitochondrial structure/activity and skel-
etal muscle phenotype/growth/functions using a mouse
model in which nNOSμ is absent (NOS1-/-). Also, NO-
induced effects and the NO pathway were dissected in
myogenic precursor cells. Our results indicate that the
deficit in NO signalling leads in skeletal muscle to alter-
ations in mitochondrial morphology, bioenergetics and
network remodelling, accompanied by defective autophagy
and the induction of a UPRmt response. These events,
while not severely altering the overall resting skeletal
muscle structure, are associated with modifications in the
Akt-mammalian target of rapamycin (mTOR) pathway
and Akt-FoxO3-mitochondrial E3 ubiquitin protein ligase
1 (Mul-1) axis and are sufficient to dysregulate skeletal
muscle growth and exercise performance.Methods
Animals
NOS1-/- animals are mice homozygous for targeted
disruption of the nNOS gene (strain name B6129S4-
NOS1tm1Plh/J) that were purchased from Jackson Labora-
tories (Bar Harbor, Maine, USA) (stock no. 002633). In
this mouse line, targeted deletion of exon 2 specifically
eliminates expression of nNOSμ [37]. NOS1-/- mice were
crossed with the wild-type B6129 to maintain the original
background and to obtain a colony of NOS1-/- mice and
wild-type littermate controls, with genotyping performed
from tail clippings. Experiments were performed on male
mice at postnatal day 10 (P10) and P120. C57BL/6 wild-
type mice (strain name C57Bl10SnJ) were purchased from
Charles River (Calco, Italy). Animals were housed in a reg-
ulated environment (23 ± 1°C, 50 ± 5% humidity) with a
12-hour light/dark cycle (lights on at 08.00 a.m.), and pro-
vided with food and water ad libitum. For specific experi-
ments, mice were killed by cervical dislocation. All studies
were conducted in accordance with the Italian law on ani-
mal care N° 116/1992 and the European Communities
Council Directive EEC/609/86. The experimental pro-
tocols were approved by the Ethics Committee of the
University of Milano. All efforts were made to reduce both
animal suffering and the number of animals used.
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Mitochondrial membrane potential in isolated transfected
fibres from flexor digitorum brevis muscles was measured
by epifluorescence microscopy based on the accumulation
of tetramethylrhodamine methyl ester (TMRM) fluores-
cence [25,29,38]. Briefly, flexor digitorum brevis myofibres
were placed in 1 ml Tyrode’s buffer and loaded with 5 nM
TMRM supplemented with 1 μM cyclosporine H for
30 minutes at 37°C. Myofibres were then observed with an
Olympus IX81 inverted microscope equipped with a CellR
imaging system (Olympus, Tokio, Japan). Sequential im-
ages of TMRM fluorescence were acquired every 60 -
seconds with a × 20 0.5, UPLANSL N A objective
(Olympus). When indicated, oligomycin (5 μM) or the
protonophore carbonylcyanide-p-trifluoromethoxyphenyl
hydrazone (FCCP, 4 μM) was added [39]. Images were ac-
quired and stored, and analysis of TMRM fluorescence
over mitochondrial regions of interest was performed
using ImageJ software (http://rsbweb.nih.gov/ij/).
Primary myogenic cell cultures
Using published protocols [25], myogenic precursor cells
(satellite cells) were freshly isolated from the muscles of
newborn C57BL/6 mice. When indicated, cells were ob-
tained from NOS1-/- mice and wild-type littermate con-
trols. Briefly, hind limb muscles were digested with 2%
collagenase-II and dispase for 10 minutes at 37°C with
gentle agitation. Contamination by non-myogenic cells
was reduced by pre-plating the collected cells onto plas-
tic dishes where fibroblasts tend to adhere more rapidly.
Dispersed cells were then resuspended in Iscove’s modi-
fied Dulbecco’s medium supplemented with 20% foetal
bovine serum, 3% chick embryo extract (custom made),
10 ng/ml fibroblast growth factor, 100 U/ml penicillin,
100 μg/ml streptomycin and 50 μg/ml gentamycin, and
plated onto matrigel-coated dishes. Differentiation was
induced by changing the medium to Iscove’s modified
Dulbecco’s medium supplemented with 2% horse serum
and the antibiotics.
Measurement of ATP formation
Tibialis anterior and diaphragm muscles were dissected,
trimmed clean of visible fat and connective tissue,
minced with scissors and digested in ATP medium, con-
taining 50 mM Tris-HCl (pH 7.4), 100 mM KCl, 5 mM
MgCl2, 1.8 mM ATP, 1 mM ethylenediaminetetraacetic
acid (EDTA), and 0.1% collagenase type V for 10 minutes
at 37°C under strong agitation. After centrifugation, the
pellet was homogenised with Ultra-Turrax T10 (Ika-lab,
Staufen, Germany) for 10 seconds at maximum speed in
ATP medium. The mitochondrial fraction, obtained by
different centrifugations (380 g and 10,000 g for five
minutes at 4°C), was then suspended in a mitochondria
resuspension buffer containing 12.5 mM Tris acetate,225 mM sucrose, 44 mM KH2PO4 and 6 mM EDTA.
Total oxidative phosphorylation (OXPHOS)-ATP in iso-
lated mitochondria was measured by the luciferin-luciferase
method, as described, with slight modifications [25]. Briefly,
mitochondria were plated in 96 wells and treated with
buffer-A (150 mM KCl, 25 mM Tris-HCl, 2 mM EDTA,
0.1% bovine serum albumin, 10 mM KH2PO4 and 0.1 mM
MgCl2 (pH 7.4) containing 0.8 M malate, 2 M glutamate,
500 mM ADP, 100 mM luciferin and 1 mg/ml luciferase.
Oligomycin (2 μg/ml) was also used to detect the presence
of glycolytic ATP. OXPHOS-ATP was measured using a
GloMax luminometer (Promega, Milan, Italy).
High-resolution respirometry
Respiratory chain defects were assessed in tibialis anterior
and diaphragm fibre bundles using published protocols
[40-42]. After transferring the tissue sample into ice-cold
BIOPS (10 mM CaK2 ethyleneglycoltetraacetic acid (EGTA)
buffer, 7.23 mM K2 EGTA buffer, 0.1 μM free calcium,
20 mM imidazole, 20 mM taurine, 50 mM 2-(N-morpho-
lino)ethanesulfonic acid hydrate, 0.5 mM dithiothreitol,
6.5 mM MgCl2 6H2O, 5.7 mM ATP and 15 mM phospho-
creatine (pH 7.1)), connective tissue was removed and the
muscle fibres were mechanically separated. Complete per-
meabilisation of the plasma membrane was ensured by
gentle agitation for 30 minutes at 4°C in 2 ml of BIOPS so-
lution containing 50 μg/ml saponin. The fibre bundles were
rinsed by agitation for 10 minutes in ice-cold mitochondrial
respiration medium (MiR05; 0.5 mM EGTA, 3 mM MgCl2,
60 mM K-lactobionate, 20 mM taurine, 10 mM KH2PO4,
20 mM Hepes, 110 mM sucrose and 1 g/l bovine serum
albumin (pH 7.1). The permeabilised muscle fibres were
weighed and added to an Oxygraph-2 k respiratory cham-
ber (Oroboros Instruments, Innsbruck, Austria) containing
2 ml of MiR06 (MiR05 supplemented with 280 U/ml cata-
lase at 37°C). Oxygen flux per muscle mass was recorded
online using DatLab software (Oroboros Instruments).
After calibration of the oxygen sensors at air saturation, a
few μl of H2O2 were injected into the chamber to reach a
concentration of 400 μM O2. In order to detect the elec-
tron flow through CI and CII mitochondrial complexes,
titrations of all of substrates, uncouplers and inhibitors were
added in series as previously described [41,42]. The meas-
urement of CIV respiration was obtained by addition of the
artificial substrates N,N,N’,N’-tetramethyl-p-phenylenediamine
dihydrochloride and ascorbate [40]. Oxygen fluxes were
corrected by subtracting residual oxygen consumption
from each measured mitochondrial steady-state. Respi-
rometry measurements were performed in duplicate on
each specimen.
Real-time quantitative PCR
Satellite cells and muscle tissue samples were homoge-
nised, and RNA was extracted using the TRIzol protocol
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lished protocols [43], after solubilisation in RNase-free
water, first-strand cDNA was generated from 1 μg of
total RNA using the ImProm-II Reverse Transcription
System (Promega). As show in Table 1, a set of primer
pairs amplifying fragments ranging from 85 to 247 bp
was designed to hybridise to unique regions of the ap-
propriate gene sequence. Real-time quantitative PCR
(qPCR) was performed using the SYBR Green Supermix
(Bio-Rad, Hercules, CA, USA) on a Roche LightCycler
480 Instrument (Roche, Basel, Switzerland). All reactions
were run in triplicate. A melt-curve analysis was per-
formed at the end of each experiment to verify that a
single product per primer pair was amplified. As a con-
trol experiment, gel electrophoresis was performed to
verify the specificity and size of the amplified qPCR
products. Samples were analysed using the Roche Light-
Cycler 480 software and the second derivative maximum
method. The fold increase or decrease was determined
relative to a calibrator after normalising to 36b4 (internal
standard) through the use of the formula 2-ΔΔCT [44].
Mitochondrial DNA (mtDNA) from muscle tissue
samples was quantified as described with slight modifi-
cations [45]. Briefly, total DNA was extracted with the
QIAamp DNA mini kit (Qiagen, Milano, Italy). Twenty
ng of total DNA was assessed by qPCR. RNaseP gene
was used as an endogenous control for nuclear DNA
and the cytochrome b gene as a marker for mtDNA.
Primer sequences are shown in Table 1.Table 1 Primer pairs designed for qPCR analysis




Cytochrome b (mt-cytb) NC_005089
MuRF1 (Trim63) NM_001039048




F: forward, R: reverse.In vivo imaging using two-photon confocal microscopy
Mitochondrial morphology and autophagosome forma-
tion in living animals were monitored in tibialis anterior
muscles transfected by electroporation with plasmids en-
coding pDsRed2-Mito or the LC3 protein fused to the
yellow fluorescent protein (YFP-LC3), as described pre-
viously [29,38,46]. Two-photon confocal microscopy in
the live, anaesthetised animals was then performed
12 days later on in situ exposure of transfected muscles
[29,38,46]. To allow the muscle to recover from the
injection-induced swelling, microscopic observation was
interrupted for two to five minutes.
Transmission electron microscopy
Tibialis anterior muscles were dissected and fixed for
one hour in a solution containing 4% paraformaldehyde
and 0.5% glutaraldehyde in 0.1 M cacodylate buffer,
pH 7.4, immobilised on a Nunc Sylgard coated Petri dish
(ThermoFisher Scientific, Waltham, MA, USA) to pre-
vent muscular contraction as previously described [47].
The muscles were rinsed in the same buffer and dis-
sected further into small blocks that were subsequently
processed for transmission electron microscopy (TEM)
as described elsewhere [48]. Briefly, the samples were
postfixed with osmium tetroxide (2% in cacodylate buf-
fer), rinsed, en bloc stained with 1% uranyl acetate in
20% ethanol, dehydrated and embedded in epoxy resin
(Epon 812; Electron Microscopy Science, Hatfield, PA,
USA) that was baked for 48 hours at 67°C. Thin sectionsPrimer sequence Amplicon
F: 5′-ATTGCTGTGGGGTTTTTCTG-3′ 247 bp
R: 5′-AACCCCAGGATTTTCAGAGG-3′
F: 5′-GCAAACACTGCCACATTCTCTC-3′ 93 bp
R: 5′-CTTGAGGGGAAAGTGAGACG-3′
F: 5′-TTCCACTAGCACCTTCTGATGA-3′ 150 bp
R: 5′-GAACACGCATTTACAGAACAA-3′
F: 5′-ACGCCATTCTACGCTCTATC-3′ 95 bp
R: 5′-GCTTCGTTGCTTTGAGGTGT-3′
F: 5′-ACCTGCTGGTGGAAAACATC-3′ 96 bp
R: 5′-CTTCGTGTTCCTTGCACATC-3′
F: 5′-TCGTGGAATGGTAATCTTGC-3′ 191 bp
R: 5′-CCTCCCGTTTCTCTATCACG-3′
F: 5′-GAAGCTGCCCTATACCCACA-3′ 85 bp
R: 5′-AGAAACCCATGGACAGCATC-3′
F: 5′-GAAGGCTCTGCGCGGACTCG-3′ 100 bp
R: 5′-CGAGAGACCGGAATGGGGCCT-3′
F: 5′-AGGATATGGGATTCGGTCTCTTC-3′ 143 bp
R: 5′-TCATCCTGCTTAAGTGAACAAACT-3′
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Ultracut E and UC7; Leica Microsystems, Wetzlar,
Germany) stained with uranyl acetate and lead citrate,
and finally examined with a Philips CM10 TEM (Philips,
Eindhoven, The Netherlands). Morphometric analysis of
mitochondrial cristae complexity was evaluated with a
stereological method. Briefly, a regular grid has been
superimposed over 10500X TEM micrographs and the
number of intersections between the grid and mitochon-
drial cristae was recorded. The same grid was used for
all the different analysis.
Protein isolation and western blotting
Satellite cells were harvested and homogenised for
10 minutes at 4°C in RIPA lysis buffer, containing 50 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 1 mM EDTA and 0.1% sodium dodecyl
sulphate (SDS). Tissue samples from muscles were homo-
genised in a lysis buffer containing 20 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1% Triton X-100, 10% glycerol,
10 mM EGTA and 2% SDS. Buffers were supplemented
with a cocktail of protease and phosphatase inhibitors
(cOmplete and PhosSTOP; Roche). Protein concentration
was determined using the bicinchoninic acid assay (Ther-
moFisher Scientific). Using published protocols [49], SDS
and β-mercaptoethanol were added to samples before
boiling, and equal amounts of proteins (40 μg/lane) were
separated by 4% to 20% SDS-polyacrylamide gel elec-
trophoresis (Criterion TGX Stain-free precast gels and
Criterion Cell system; Bio-Rad). Proteins were then trans-
ferred onto a nitrocellulose membrane using a Bio-Rad
Trans-Blot Turbo System. The membranes were probed
using the following primary antibodies as indicated in the
text: goat polyclonal anti-HSP60 (N-20) and rabbit poly-
clonal anti-MyoD (C-20) (Santa Cruz Biotechnology,
Dallas, TX, USA), mouse monoclonal anti-ClpP and rabbit
polyclonal anti-LC3B (Sigma-Aldrich, Saint Louis, MO,
USA), rabbit polyclonal anti-Mul-1 (Abcam, Cambridge,
UK), mouse monoclonal anti-sarcomeric myosin (MF20)
(Developmental Studies Hybridoma Bank, Iowa City, IA,
USA), rabbit polyclonal anti-phospho-FoxO3a (Ser253),
rabbit polyclonal anti-phospho-S6 ribosomal protein
(Ser240/244), rabbit monoclonal anti-phospho-4E-BP1
(Thr37/46) (263B4) and rabbit polyclonal anti-phospho-
Akt (Ser473) (Cell Signaling Technology, Danvers,
MA, USA). After the incubation with the appropriate
horseradish-peroxidase-conjugated secondary antibody
(Cell Signaling Technology), bands were visualised using
the Bio-Rad Clarity Western ECL substrate with a Bio-Rad
ChemiDoc MP imaging system. To monitor for potential
artefacts in loading and transfer among samples in dif-
ferent lanes, the blots were routinely treated with the
Restore Western Blot Stripping Buffer (ThermoFisher
Scientific) and reprobed with rabbit polyclonal anti-calnexin(GeneTex, Irvine, CA, USA), goat polyclonal anti-actin
(I-19) or rabbit polyclonal anti-GAPDH (FL-335) primary
antibodies (Santa Cruz Biotechnology). When appropriate,
rabbit polyclonal anti-FoxO3a (75D8), rabbit monoclonal
S6 ribosomal protein (54D2), rabbit polyclonal 4E-BP1
(53H11), and rabbit polyclonal Akt primary antibodies
(Cell Signaling Technology) that recognise the protein in-
dependently of its phosphorylation state were also used in
reprobing experiments.
Confocal microscopy of myogenic precursor cells
Cells were plated in eight-well Nunc LabTeck Chamber
slides (ThermoFisher Scientific). When indicated cells
were transfected with YFP-LC3 plasmid. Transfections
were performed with the Lipofectamine LTX with Plus
reagent (Invitrogen-Life Technologies) according to the
manufacturer’s instructions. The cells were used 24 hours
after transfection in the various experimental settings
described. For confocal imaging, the cells were fixed in
paraformaldehyde and washed in phosphate-buffered sa-
line [50]. To prevent nonspecific background, cells were
incubated in 10% goat serum/phosphate-buffered saline
followed by probing with the primary antibody mouse
monoclonal anti-cyclophillin D (Abcam). Cells were then
incubated with the secondary antibody, Alexa Fluor 546
dye-conjugated anti-mouse IgG (Molecular Probes-Life
Technologies, Monza, Italy). Slides were placed on the
stage of a TCS SP2 Laser-Scanning Confocal microscope
(Leica Microsystems) equipped with an electronically
controlled and freely definable Acousto-Optical Beam
Splitter. Images were acquired with x63 magnification
oil-immersion lenses. Analyses were performed using
Imagetool software (Health Science Center, University of
Texas, San Antonio, TX, USA). Images of cells express-
ing YFP-LC3 were thresholded by using the automatic
threshold function.
Immunohistochemistry and histology
Laminin and haematoxylin and eosin (H & E) staining
were performed as previously described [47,51]. To meas-
ure the cross sectional area (CSA) of myofibres, muscle
sections were stained with an anti-laminin A antibody
(L1293; Sigma-Aldrich). Laminin, a cell-adhesion mol-
ecule strongly expressed in the basement membrane of
skeletal muscle, was detected using an appropriate sec-
ondary antibody. Morphometric analyses were performed
on sections collected from similar regions of each muscle
using a Leica DMI4000 B automated inverted microscope
equipped with a DCF310 digital camera. Image acquisition
was controlled by the Leica LAS AF software. The ImageJ
software was used to determine the CSA of 1,000 to 3,000
individual fibres from at least two different fields for each
muscle section. Four to nine sections from each muscle
were analysed. For histological analyses, serial muscle
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standard procedures. The number of fibres was counted
and analysed using the ImageJ software.
Single myofiber isolation of hind limb muscle and nu-
clei immunofluorescence on single fibers was performed
as previously described [8]. Nuclei of 30 individual fibres
from each muscle were analysed.
Whole body tension
The whole body tension (WBT) procedure was used to
determine the ability of mice to exert tension in a for-
ward pulling manoeuvre that is elicited by stroking the
tail of the mice [52]. The tails were connected to a Grass
FT03 transducer (Astro-Med, West Warwick, RI, USA)
with a 4.0 silk thread (one end of the thread being tied
to the tail and the other end to the transducer) [47].
Each mouse was placed into a small tube constructed of
a metal screen with a grid spacing of 2 mm. The mice
entered the apparatus and exerted a small resting ten-
sion on the transducer. Forward pulling movements
were elicited by a standardised stroke of the tail with
serrated forceps, and the corresponding forward pulling
tensions were recorded using a Grass Polyview recording
system (Astro-Med). Between 20 and 30 strokes of the
tail forward pulling tensions were generally recorded
during each session. The WBT was determined by divid-
ing the average of the top ten or top five forward pulling
tensions, respectively, by the body weight and represent
the maximum phasic tension that can be developed over
several attempts [52]. It is important to note that treat-
ments or conditions which primarily alter muscle mass
without changing the tension developed per unit of
muscle mass produce corresponding alterations in forward
pulling tension that are not associated with changes in
either WBT 5 or WBT 10 [52,53].
Treadmill running
Animals were made to run on a standard treadmill
machine (Columbus Instruments, Columbus, OH, USA)
either on a 0% grade or tilted 10% downhill starting at a
warm-up speed of 5 m/minute for five minutes [54]. Every
subsequent five minutes, the speed was increased by 5 m/
minute until the mice were exhausted. Exhaustion was de-
fined as the inability of the animal to return to running
within 10 seconds after direct contact on an electric stimu-
lus grid. Running time was measured and running distance
calculated. Distance is the product of time and speed of
the treadmill.
As a measure of membrane permeability, the Evans blue
dye (EBD) assay was used [47]. A concentration of 5 μg/μl
EBD prepared in physiological saline was injected intraven-
ously through the tail vein. Injections (50 μl/10 g body
weight) were performed 20 to 30 minutes after treadmill
running. Mice were sacrificed 24 hours after EBD injection.tibialis anterior muscle sections (20 to 30 from each
muscle) were then collected and the immunofluorescence
of EBD-positive fibres was imaged using Texas red red fil-
ter. Creatine kinase (CK) serum levels (units per litre) were
measured in blood samples obtained from the tail vein of
mice after treadmill running. The blood was centrifuged at
13,000 × g at 4°C and the supernatant used to measure CK
activity in an indirect colorimetric assay (Randox Labora-
tories, Crumlin, Northern Ireland, UK) [16,18].
Statistics
Upon verification of normal distribution, the statistical
significance of the raw data between the groups in each
experiment was evaluated using the unpaired Student’s
t-test (single comparisons) or one way analysis of vari-
ance (ANOVA) followed by the Newman-Keuls post-test
(multiple comparisons). The GraphPad Prism software
package (GraphPad Software, La Jolla, CA, USA) was
used. After statistics (raw data), data from different ex-
periments were represented and averaged in the same
graph. The results are expressed as means ± SEM of the
indicated n values.
Chemicals
pDsRed2-Mito was a gift of Prof. Luca Scorrano (University
of Padova, Padova, Italy). Dispase was purchased from
Gibco-Life Technologies (Monza, Italy). TMRM and the
secondary antibody for laminin experiments were obtained
from Molecular Probes-Life Technologies. Iscove’s modified
Dulbecco’s medium, penicillin, streptomycin, gentamycin,
horse serum, and foetal bovine serum were purchased from
Euroclone (Pero, Italy). Matrigel was obtained from BD-
Bioscience (Milano, Italy). Primer pairs were obtained from
Primmbiotech (Milano, Italy). Fibroblast growth factor was
purchased from Tebu-bio (Milano, Italy). DETA-NO and
KT5823 were obtained from Merck Millipore (Darmstadt,
Germany). ODQ and cyclosporine were purchased from
Enzo Life Sciences (Farmingdale, NY, USA). Lω-arginine
methylester (L-NAME) and the other chemicals were pur-
chased from Sigma-Aldrich.
Results
nNOSμ deficiency leads to mitochondrial dysfunction
Mitochondrial function in skeletal muscles of adult
NOS1-/- mice, that is, at P120, was dissected and com-
pared with that of the respective age-matched wild-type
littermattes (control). Mitochondrial membrane potential
was monitored in isolated fibres from flexor digitorum bre-
vis muscles loaded with TMRM, a potentiometric fluores-
cent dye. TMRM accumulates in the mitochondria that
maintain a polarised mitochondrial membrane potential.
A latent mitochondrial dysfunction masked by the ATP
synthase operating in a reverse mode, that is, to consume
ATP in order to maintain the mitochondrial membrane
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tor oligomycin [25]. In agreement with previous reports
[29], addition of oligomycin to control mice fibres did not
cause immediate changes in membrane potential even
after extensive incubation (Figure 1A). Conversely, mito-
chondria in fibres of NOS1-/- mice underwent marked de-
polarisation after oligomycin.
We investigated whether the latent mitochondrial dys-
function observed in muscles of NOS1-/- mice affectedFigure 1 Mitochondrial metabolism is impaired in skeletal muscles of N
and NOS1-/- mice at P120. (A) Mitochondrial membrane potential measured
and treated with 5 μM oligomycin (Olm) or 4 μM FCCP. TMRM staining was m
per experimental group. Data are expressed by setting the initial value as 1. (B
diaphragm muscles, at 10 minutes after substrate addition. Data are expressed
isolated from tibialis anterior and diaphragm muscles, supplied with specific C
Methods. (E) Quantitative analysis of the mtDNA copy number. Data are expr
represents the data obtained from at least five different animals per experime
control.the muscle bioenergetic parameters. To this end, we
measured ATP generation from OXPHOS in isolated
mitochondria of tibialis anterior and diaphragm muscle
fibres. As shown in Figure 1B, total OXPHOS-generated
ATP was significantly lower in NOS1-/- mice when
compared to control.
We then analysed the mitochondrial bioenergetics in
intact fibres using an in situ approach measuring oxygen
consumption by high resolution respirometry. By thisOS1-/- mice. Fibres were isolated from different muscles of wild-type
in fibres isolated from flexor digitorum brevis muscles, loaded with TMRM
onitored in six to ten fibres obtained from at least three different animals
) ATP production on mitochondria isolated from tibialis anterior and
by setting the initial value as 1. (C-D) Oxygen consumption on fibres
I, CII and CIV mitochondrial complex substrates, as indicated in the
essed by normalizing mtDNA values versus nuclear DNA. Each histogram
ntal group. * P <0.05 and ** P <0.01 versus the respective wild-type
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specific OXPHOS capacity with physiological combina-
tions of CI mitochondrial complex substrates was similar
in both tibialis anterior and diaphragm of NOS1-/- and
control mice (Figure 1C-D). In contrast, the CII-linked
respiratory capacity in tibialis anterior of NOS1-/- mice
was lower than that in control muscle fibres, while no
difference was observed in the diaphragm. In both tibi-
alis anterior and diaphragm of NOS1-/- mice the CIV-
linked respiratory capacity decreased significantly with
respect to the controls. Of interest, qPCR analysis of
mtDNA levels in tibialis anterior and diaphragm mus-
cles did not reveal any difference between NOS1-/- and
control mice (Figure 1E) suggesting that mitochondrial
mass was not affected and defects in OXPHOS were due
to dysfunctional mitochondria.
nNOSμ deficiency affects mitochondrial network
remodelling, UPRmt and autophagy
Alterations in the content, shape or function of the
mitochondria have been associated with muscle homeo-
stasis [31,55]. To identify the changes in mitochondrial
network morphology, tibialis anterior muscles of P120
NOS1-/- and wild-type control mice were imaged using
pDsRed2-Mito, a mitochondrially targeted red fluores-
cent protein, by in situ two-photon confocal microscopy
[29,38,46]. NOS1-/- mice showed a disorganised mito-
chondrial network (Figure 2A). Accordingly, ultrastruc-
tural analyses by TEM (Figure 2B and Additional file 1:
Figure S1A) revealed changes in the subsarcolemmal
mitochondria of tibialis anterior muscles of NOS1-/- mice
that exhibited, in thin sections, a significant increase in
mitochondrial surface area (Figure 2C) and a significant
decrease in the density of the cristae (Figure 2D), as com-
pared with the controls. The same evaluation was per-
formed on subsarcolemmal mitochondria from diaphragm
muscle with similar results (data not shown). The analysis
of intermyofibrillar mitochondria (see Additional file 1:
Figure S1B) showed a pattern of enlarged mitochondria
indicating that the presence of these mitochondrial alter-
ations in NOS1-/- mice muscle is not restricted to the
sarcolemma but is a more general phenomenon.
We then analysed two downstream processes linked to
mitochondrial stress: UPRmt and autophagy. In tibialis
anterior muscles of P120 NOS1-/- mice the expression
of the nuclearly-encoded mitochondrial chaperones
HSP60 and the protease ClpP, which correlates with the
level of unfolded proteins in mitochondria [56,57], was
found to be higher than in the controls (Figure 2E). In
addition, the two-photon confocal microscopy of the
YFP-LC3 [29,38,46] revealed the presence of LC3-
positive vesicles, an established marker of autophago-
some formation [58], in tibialis anterior muscles of P120
NOS1-/- mice (Figure 2F). Furthermore, TEM analysisshowed the presence of autophagic vacuoles and multi-
vesicular bodies, indicative of an active autophagic path-
way [59], in tibialis anterior and diaphragm muscles of
P120 NOS1-/- mice (Figure 2B and Additional file 1:
Figure S1C). The enhanced autophagy in the absence of
nNOSμ in skeletal muscle was confirmed by Western
blot analysis. The appearance of a faster migrating band
of LC3 protein due to its lipidation and cleavage is a
common marker of autophagy induction [58]. As shown
in Figure 2G, tibialis anterior muscles of P120 NOS1-/-
mice exhibited increased lipidated LC3 levels when com-
pared to control mice. Similar results on LC3 conversion
were obtained analysing diaphragm muscle samples (see
Additional file 1: Figure S1D).
NO signalling regulates UPRmt and autophagy machinery
Activation of the NO-dependent enzyme guanylate
cyclase, with formation of cyclic guanosine monophosphate
(cGMP) and activation of a variety of downstream signal-
ling cascades, including cGMP-dependent-protein kinases
(PKG), contributes significantly to mediate the physio-
logical effects of NO in muscle [2,5,60]. To investigate the
involvement of the cGMP-dependent signalling on UPRmt
and autophagy, myogenic precursor cells were differenti-
ated for six hours in the absence (control) or in the pres-
ence of the inhibitor of NOS L-NAME (6 mM), the
inhibitor of guanylate cyclase ODQ (10 μM), and the in-
hibitor of PKG KT5823 (1 μM) [61-66]. L-NAME, ODQ
and KT5823 treatment increased the expression of HSP60
and ClpP protein. The NO donor DETA-NO (80 μM) and
the membrane-permeant cGMP analogue 8Br-cGMP
(2.5 mM) [62-66] reversed the effects of L-NAME and
ODQ, respectively (Figure 3A).
In another set of experiments, cells were transiently
transfected with YFP-LC3 and then differentiated. As
shown by confocal microscopy fluorescence analysis of
LC3 and the mitochondrial matrix-specific protein cyclo-
phillin D (Figure 3B), in control cells LC3 staining was dif-
fuse and the majority of mitochondria were in the
elongated form, indicating myogenic differentiation [25]
and a low rate of autophagy. L-NAME, ODQ, and KT5823
treatment, while inducing mitochondrial fragmentation,
resulted in LC3 localisation into dot cytoplasmic struc-
tures, as compared to the diffuse cytoplasmic distribution
observed in control cells. The effects of L-NAME and
ODQ were prevented by DETA-NO and 8Br-cGMP,
respectively.
NO control of autophagy was assessed further by analys-
ing the expression of relevant markers of the autophagic
signalling pathway, namely LC3, by western blotting and
p62, Bnip3 and Atg4 by qPCR analysis [58,67]. L-NAME,
ODQ and KT5823 treatments increased lipidated LC3
conversion in differentiated satellite cells and LC3 lipida-
tion induced by L-NAME and ODQ was blocked by
Figure 2 Mitochondrial morphology, UPRmt and autophagy in skeletal muscles of NOS1-/- mice. Tibialis anterior muscles were isolated
from wild-type and NOS1-/- mice at P120. (A) In vivo imaging of the mitochondrial network by two-photon confocal microscopy. Muscles were
transfected with the mitochondrially targeted red fluorescent protein pDsRed2-Mito. The images are representative of results obtained from at
least five different animals per experimental group. Scale bar: 10 μm. (B) TEM images detecting the presence of abnormal, enlarged subsarcolemmal
mitochondria (asterisks) or autophagic vacuoles (arrowheads) in NOS1-/- muscles. The inset depicts a multivesicular body in NOS1-/- fibres taken at higher
magnification. The images are representative of results obtained from at least three different animals per experimental group. (C-D) Subsarcolemmal
mitochondrial ultrastructure analysis by TEM. Data represent the quantification of the mitochondrial area and morphometric analysis of mitochondrial
cristae complexity. Each histogram represents the data obtained from at least three different animals per experimental group. * P <0.05 and ** P <0.01
versus the respective wild-type control. (E) Western blot analysis of HSP60 and ClpP expression. Actin was used as the internal standard. The image is
representative of results obtained from at least five to seven different animals per experimental group. (F) In vivo imaging of autophagosome formation by
two-photon confocal microscopy. Muscles were transfected with YFP-LC3. The images are representative of results obtained from at least five different
animals per experimental group. Scale bar: 10 μm. (G) Western blot analysis of LC3 lipidation. Actin was used as the internal standard. The image is
representative of results obtained from at least 10 different animals per experimental group.
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addition, cells treated with L-NAME, ODQ and KT5823
expressed higher levels of transcripts encoding p62, Bnip3
and Atg4 (Figure 4B).
Deficient nitric oxide signalling promotes FoxO3-Mul-1
axis
Catabolic conditions activate FoxO transcription factors,
which stimulate the ubiquitin-proteasome system as a
response to skeletal muscle-wasting [31,55]. FoxO3 ac-
tivity is necessary and sufficient for the induction of au-
tophagy in skeletal muscle [38]. FoxO3 translocationfrom the cytoplasm to the nucleus determines the direct
transcriptional activation of genes essential to autopha-
gosome formation, namely p62, Bnip3 and Atg4 [58,67].
Enhanced activity of FoxO transcription factors has also
been associated with disruption of mitochondrial func-
tion and organisation leading to impaired skeletal
muscle function and development [29]. As shown in
Figure 5A, C, phosphorylated FoxO3 levels in tibialis
anterior and diaphragm muscles of P120 NOS1-/- mice
were lower than in the controls. In addition, tibialis an-
terior and diaphragm muscles of NOS1-/- mice overex-
pressed the protein corresponding to mitochondrial
Figure 3 NO signalling, UPRmt, and autophagy on myogenic precursor cells. Cells were differentiated for six hours in the absence (control)
or in the presence of L-NAME (6 mM), ODQ (10 μM), KT5823 (1 μM), L-NAME + DETA-NO (80 μM), and ODQ +8 Br-cGMP (2.5 mM). (A) Western
blot analysis of HSP60 and ClpP expression. Actin was used as the internal standard. (B) Confocal microscopy imaging of cells transfected with
YFP-LC3. Mitochondrial morphology was detected by mitochondrial matrix-specific protein cyclophillin D (CypD) staining. Scale Bar: 10 μm.
Images are representative of at least three to five independent experiments..
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recently reported to be upregulated in muscle through
FoxO3 transcription factors and promoting mitochon-
drial fission, depolarization and mitophagy [68,69]. As
shown in Figure 5E, in vitro treatment of differentiated
myogenic precursor cells from wild-type control mice
with L-NAME, ODQ and KT5823 increased Mul-1 pro-
tein expression. The effects induced by L-NAME and
ODQ were blocked by DETA-NO and 8Br-cGMP, re-
spectively. In tibialis anterior and diaphragm muscles of
P120 NOS1-/- mice, qPCR analysis of other E3 ubiquitin
ligases, atrogin-1 and MuRF1, involved in muscle loss
[69,70], ruled out a nNOSμ-dependent modulation of
their expression (Figure 5F, G). Also, the differencesobtained with MUSA1 analysis are difficult to correlate
with nNOSμ deficiency. These findings indicate that the
effects of nNOSμ absence on E3 ubiquitin ligases mainly
affect expression of Mul-1 gene.
nNOSμ deficiency affects muscle growth
We evaluated the effects of the absence of nNOSμ on
skeletal muscle phenotype. Tibialis anterior, gastrocne-
mius, soleus, and extensor digitorum longus muscles were
dissected and weighed. Since the body weight and the
visceral adipose tissue of NOS1-/- male mice were sig-
nificantly lower than wild-type control (see Additional
file 2: Figure S2A-B) [71] we calculated the muscle size
relative to body weight [72]. As shown in Figure 6A and
Figure 4 NO signalling and autophagic pathway on myogenic precursor cells. (A) Western blot analysis of LC3 lipidation in cells
differentiated for six hours in the absence or in the presence of L-NAME (6 mM), ODQ (10 μM), KT5823 (1 μM), L-NAME + DETA-NO (80 μM), and
ODQ +8 Br-cGMP (2.5 mM). Actin was used as the internal standard. Image is representative of at least five independent experiments. (B) qPCR
analysis of mRNA levels for p62, Bnip3 and Atg4 in cells differentiated for six hours in the absence (control) or in the presence of L-NAME ODQ,
and KT5823. Values are expressed as the fold change over control. Each histogram represents the data obtained from at least five independent
experiments. * P <0.05 versus respective control.
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muscles for the P120 NOS1-/- mice was significantly
lower than the relative mass of the muscles for the con-
trol mice. This excludes the possibility that the changes
in muscle mass are simply due to an overall change in
size of the mice.
The overall morphology of the tibialis anterior and
diaphragm muscle in P120 NOS1-/- mice was normal,
without pathological features of necrosis, macrophage
infiltration and centronucleated fibres (see Additional
file 2: Figure S2D). In addition, the number of fibres in
tibialis anterior muscles was comparable in both
NOS1-/- and control mice (Figure 6B). By contrast, lam-
inin staining of tibialis anterior and diaphragm, used to
identify individual muscle fibres, revealed a significant
decrease in the mean CSA of tibialis anterior and dia-
phragm sections in P120 NOS1-/- mice when compared
with control (Figure 6C-H).The examination of multiple time points was then
carried out in order to establish a possible link between
the changes in mitochondrial homeostasis and the re-
duction in muscle size. The CSA (Figure 7A-C) and the
number of myonuclei (Figure 7D) of hind limb muscle
fibres were significantly decreased in P10 NOS1-/-
mice, when compared with the respective control.
Muscle growth during post-natal development (P0 to
P21), but not at later stages, is accompanied by a con-
tinuous increase in the number of myonuclei resulting
from satellite cell fusion [69,73]. As shown in Figure 7E,
NOS1-/- cells exhibited lower levels of myosin and
MyoD, which are markers of myogenic differentiation,
as compared to control cells. Interestingly, CycloD stain-
ing of differentiating myogenic precursor cells indicated
that the absence of nNOSμ induces diffuse mitochondrial
fragmentation (Figure 7F) [25]. Taken together, our data
argue that the absence of nNOSμ induces mitochondrial
Figure 5 NO signalling, FoxO3, and ubiquitin ligases. Western blot analysis of phosphorylated FoxO3 levels (pFoxO3) or mitochondrial
ubiquitin ligase Mul-1 expression in tibialis anterior (A-B) and diaphragm (C-D) of wild-type and NOS1-/- mice at P120. FoxO3 or actin were used
as the internal standard. The images are representative of results obtained from at least four to ten different animals per experimental group.
(E) Western blot analysis of Mul-1 expression in myogenic precursor cells differentiated in the absence or in the presence of L-NAME (6 mM),
ODQ (10 μM), KT5823 (1 μM), L-NAME + DETA-NO (80 μM) and ODQ +8 Br-cGMP (2.5 mM). Actin was used as the internal standard. The image is
representative of at least five independent experiments. qPCR analysis of mRNA levels for atrogin-1, muRF1 and MUSA1 in tibialis anterior (F) and
diaphragm (G) muscles of wild-type and NOS1-/- mice at P120. Values are expressed as the fold change over wild-type. Each histogram represents
the data obtained from at least five to eight different animals per experimental group. * P <0.05 versus the respective wild-type control.
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tiation, thus impairing fibre growth.
At P30 we found that the CSA of tibialis anterior was
significantly decreased in NOS1-/- mice, when com-
pared with controls (Figure 8A-C). In this crucial time
of muscle growth we also measured the activation of the
Akt-mTOR pathway as a positive regulator [55,69,73,74].
As shown in Figure 8D, phosphorylated levels of S6 ribo-
somal protein, 4E-BP1 and Akt in tibialis anterior mus-
cles of NOS1-/- mice were lower than in the controls.
FoxO3 proteins are phosphorylated by Akt, which ren-
ders them inactive; this may explain why phosphorylated
FoxO3 levels were found to be lower as well, while Mul-
1 was overexpressed (Figure 8E). Of importance, both
events are correlated with muscle mitochondrial dys-
function and growth [29,55,68,69,73,74].Using NOS1-/- mice it has been previously shown that
nNOS modulates the mechanism of disuse-induced atro-
phy via FoxO transcription factors [75]. Our observation
that at P10, P30 (see Additional file 2: Figure S2E-F) and
P120 (Figure 5E-F) NOS1-/- and control mice expressed
similar levels of transcripts encoding the classical atro-
genes atrogin-1 and MuRF1 [69,70,75], indicates that the
atrophy pathways do not play a key role in the develop-
ment of NOS1-/- muscles.
nNOSμ deficiency affects muscle function
We evaluated whether the absence of nNOSμ affected
skeletal muscle function. The WBT measurement deter-
mines the total phasic forward pulling tension exerted
by the fore and hind limb muscles and reflects the max-
imal acute phasic force the mouse can achieve to escape
Figure 6 Skeletal muscle phenotype of wild-type and NOS1-/- mice at P120. (A) Weight of tibialis anterior, gastrocnemius, soleus, and
extensor digitorum longus (EDL) muscles. The muscle size is relative to body weight. Each histogram represents the data obtained from at least 10
different animals per experimental group. (B) The number of myofibres in tibialis anterior. Each histogram represents the data obtained from at
least four to five different animals per experimental group. Laminin staining of tibialis anterior (C-E) and diaphragm (F-H) muscles. (C, F)
Immunohistochemical images. Scale bar: 100 μm. (D, G) Representative distribution of CSA values. (E, H) Quantification of CSA. Images and
quantifications represent the data obtained from at least four to seven different animals per experimental group. *P <0.05, **P <0.01, and
***P <0.001 versus the respective wild-type control.
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the WBT normalised for body weight in P120 NOS1-/-
mice was significantly lower than in the wild-type con-
trol, consistent with an unpaired muscle specific force
output in the absence of nNOSμ.
We also examined the muscle resistance to fatigue: we
subjected NOS1-/- mice to treadmill running, that mea-
sures resistance to fatigue during a forced exercise, and ex-
amined both exercise performance and tolerance. As
shown in Figure 9B, the total distance run by NOS1-/-
mice during one bout of exhaustive treadmill running (day
1) was significantly lower when compared to controls.
This reduction in performance of NOS1-/- mice was also
observed after repeated challenges: NOS1-/- mice showedsignificant exercise intolerance after repetitive exercise
challenges, while control mice at day 3 showed even im-
proved exercise capacity, compared to day 1. NOS1-/-
mice also exhibited a significantly decreased treadmill
runtime to exhaustion (Figure 9C).
We then assessed the structure/damage of skeletal
muscle myofibres after exercise. TEM analysis performed
in tibialis anterior muscles of P120 NOS1-/- mice after the
treadmill running showed marked ultrastructural changes,
as, for instance, defects in the organisation of the contract-
ile apparatus (sarcomere), that were observed neither in
the wild-type mice nor in unchallenged NOS1-/- mice
(Figure 9D). The features observed in challenged NOS1-/-
mice might be a direct consequence of denervation events
Figure 7 Skeletal muscle phenotype of wild-type and NOS1-/- mice at P10. (A-C) Laminin staining of hind limb muscles. (A)
Immunohistochemical images. Scale bar: 100 μm. (B) Representative distribution of CSA values. (C) Quantification of CSA. Images and
quantifications represent the data obtained from at least five different animals per experimental group. (D) Number of myonuclei per fibre in
hind limb muscles. Each histogram represents the data obtained from at least three different animals per experimental group. (E) Western blot
analysis of myosin (MF20) and MyoD expression in myogenic precursor cells isolated from wild-type and NOS1-/- mice and differentiated for
increasing times. Calnexin was used as the internal standard. Images are representative of at least three independent experiments. (F) Confocal
microscopy imaging of myogenic precursor cells isolated from wild-type and NOS1-/- mice and differentiated for 48 hours. Mitochondrial morphology
was detected by mitochondrial matrix-specific protein cyclophillin D staining. Scale Bar: 10 μm. Images are representative of at least three independent
experiments. * P <0.05 versus the respective wild-type control.
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end-plates lacking the presynaptic nerve ending (data not
shown). As shown in Figure 9E, tibialis anterior muscles
of P120 NOS1-/- mice after the treadmill running dis-
played an increased uptake versus wild-type of EBD, which
stains damaged myofibres [47]. As an in vivo indicator of
skeletal muscle damage we also analysed the serum levels
of CK, a skeletal muscle enzyme released during fibre de-
generation whose activity increased in dystrophic animals
[16,18]. As expected, in NOS1-/- mice after the treadmill
running, the serum CK activity was found to be signifi-
cantly higher than that in the wild-type mice (Figure 9F).
Discussion
This study documents that nNOSμ deficiency, while se-
verely altering the structure and bioenergetics potential
of skeletal muscle mitochondria does not impact signifi-
cantly on the overall resting muscle structure, apart from
reducing muscle mass and the CSA of the myofibres of
specific muscles. When the muscle is exposed to work-
loads, however, the consequences of nNOSμ deficiency
become apparent, with a significantly reduced resistance
of the muscles accompanied by increased sensitivity to
exercise-induced damage. This establishes for the firsttime a link between a deficit in NO signalling, mito-
chondrial alterations and skeletal muscle impairments.
The first result emerging from our analysis is that
nNOSμ deficiency is per se sufficient to induce profound
defects in mitochondria, with alterations in mitochondrial
distribution, shape, morphology and size accompanied by
a latent mitochondrial dysfunction such that energy gener-
ation is impaired. Nitric oxide has several key functions in
mitochondria: it inhibits mitochondrial fission, induces
mitochondrial biogenesis and controls mitochondrial re-
spiratory rate by reversible inhibition of complex IV in the
mitochondrial respiratory chain [25,76,77]. Furthermore,
it controls the expression of several enzymes in the Krebs
cycle [78]. Derangement of these mitochondrial functions
is most likely at the basis of the multiple mitochondrial
deficits we observed in NOS1-/- mice.
Of importance, we found that this overall mitochon-
drial dysfunction was accompanied both in intact myofi-
bres in vivo and in isolated satellite cells in vitro by an
enhanced UPRmt response. It has been hypothesised that
the UPRmt is activated prior to the induction of autoph-
agy [79]; in particular, that the autophagy pathway is ac-
tivated when mitochondria cannot maintain a polarised
membrane potential despite UPRmt activation. We found
Figure 8 Skeletal muscle phenotype of wild-type and NOS1-/- mice at P30. (A-C) Laminin staining of tibialis anterior muscles. (A)
Immunohistochemical images. Scale bar: 100 μm. (B) Representative distribution of CSA values. (C) Quantification of CSA. Images and
quantifications represent the data obtained from at least five different animals per experimental group. Western blot analysis in tibialis anterior:
(D) phosphorylated S6, 4E-BP1 and Akt levels, (E) phosphorylated FoxO3 levels or mitochondrial ubiquitin ligase Mul-1 expression. S6, 4E-BP1,
Akt, FoxO3 or actin were used as the internal standard. The images are representative of results obtained from at least four different animals per
experimental group. *P <0.05 versus the respective wild-type control.
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agy and increased expression of molecules relevant to
autophagic signalling, namely p62, Bnip3 and Atg4. This
suggests that nNOSμ deficiency leads to a sufficiently se-
vere mitochondrial deficit that cannot be restored by
UPRmt. The enhanced autophagic and UPRmt response
were normalised when the cGMP-dependent signalling
was activated, indicating that these events are controlled
by NO via its physiological second messenger cGMP.
The second relevant information is that an altered NO
system leads to impairment of muscle function that is
selective to specific parameters and unmasked during
exercise. In particular we found that skeletal muscles in
the absence of nNOSμ are smaller relative to the rest of
the body, thus indicating that muscle mass decrease was
not simply attributable to a generalised decreased body
mass tissues (including adipose tissue) and likely due to
a specific reduction in the size of the muscle fibres
themselves. In agreement with this, NOS1-/- mice mus-
cles (that is, tibialis anterior and diaphragm) displayed
smaller myofibre CSA when compared to littermatecontrols, although they did not show any pathological
features reminiscent of muscle damage, such as inflam-
mation, necrosis or fibrosis. Similar morphological data
were obtained in male NOS1-/- mice backcrossed onto
the B6129 background (our experimental model) [71] or
backcrossed onto the C57BL/6 background [80], al-
though in the latter model no difference in tibialis anterior
muscle mass relative to body mass was reported. That
the decrease in muscle mass is due to mechanisms other
than the decrease in body mass was recently suggested
using NOS1-/- mdx mice [72]. The deficiency of nNOSμ
is also accompanied by muscle ageing [81] and fibre
growth was prevented in the NOS1-/- mice model of
skeletal muscle hypertrophy [82] and NOS1-/- mdx
mice [72]. In a recent study, no difference in the weight
and CSA of tibialis anterior muscles from NOS1-/- and
control was also reported but the animal background
was not indicated [83]. Discrepancies in these studies
may be explained, at least in part, by strain-specific
modulation of the nNOSμ-regulated phenotype, a hy-
pothesis substantiated by the observation, by the same
Figure 9 Skeletal muscle function in wild-type and NOS1-/- mice. (A) WBT measurements determined by dividing the average of the top ten
or top five forward pulling tensions, respectively, by the body weight. (B) Running distance calculated during one bout of exhaustive treadmill
running (day 1) and after repeated challenges (days 2 and 3). (C) Treadmill runtime to exhaustion calculated as the averages obtained at day 1 to
3. Each histogram represents the data obtained from at least four to five different animals per experimental group. (D) TEM analysis performed in
tibialis anterior muscles of both unchallenged (no run) and challenged (exhaustive running) mice. The images are representative of results
obtained from at least three different animals per experimental group. (E) EBD uptake in tibialis anterior muscles after the treadmill running. Scale Bar:
100 μm. The images are representative of results obtained from at least four different animals per experimental group. (F) CK serum levels (units per
litre) of mice after treadmill running. Each histogram represents the data obtained from at least four different animals per experimental group. *P <0.05,
**P <0.01 and ***P <0.001 versus the respective wild-type control. WBT and treadmill running were performed on animals at P120.
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mice backcrossed onto the C57BL/6 and the B6129 back-
ground [37,71,80].The functional studies revealed two important aspects
of the role of NO in skeletal muscle. Firstly, the fact that
NOS1-/- mice in our in vivo experiments exhibited a
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fatigue during a forced exercise indicates that nNOSμ is
important to maintain skeletal muscle strength and the
animal’s ability to perform in repetitive exercise training.
Our results in vivo are in line with a previous study with
an in situ approach reporting that nNOSμ-deficient tibi-
alis anterior muscles exhibit a reduced force production
and a specific deficit in adapting to exercise and develop
profound fatigue upon repeated contraction [71]. An ex-
cessive fatigue has been also observed in NOS1-/- mice
and wild-type mice treated with a nNOS inhibitor [12].
A specific and intrinsic deficit in muscle force produc-
tion has been recently reported in NOS1-/- mdx mice,
although muscle fatigue was unaffected by nNOS deple-
tion [72]. Secondly, our data on muscle phenotype and
CK measurements after treadmill running indicate that
nNOSμ deficiency induces muscle degeneration/damage
post-exercise. This raises the possibility that nNOSμ-
deprived muscles cannot activate protective responses.
Accordingly, NOS1-/- mdx mice displayed increased
susceptibility to eccentric contraction-induced muscle
damage [72]. In addition, expression of a muscle-specific
nNOS transgene prevents muscle membrane injury dur-
ing modified muscle use [84]. In this respect, there is a
general agreement that NO produced by nNOS plays an
important role in muscle repair in chronic conditions
[5,8,9] although the use of NOS1-/- mice suggested that
nNOS is not essential to functional recovery after acute
injury [80].
The third important observation is the correlation be-
tween mitochondrial defects and muscle impairment.
Alterations in the content, shape or function of the mito-
chondria appear to occur in damaged muscle and inhib-
ition of mitochondrial fission protects from muscle loss
during fasting [29]. Recent findings have also underlined
the crucial role of autophagy in the control of muscle mass
and functions [29,31,55,69]. Autophagy derangement is in-
volved in a number of inherited muscle diseases [31-33].
Of interest, mitochondria are involved in regulating au-
tophagy [30]. In addition, skeletal muscle was shown to be
sensitive to the physiological stressors that trigger the
UPRmt [35,36] and UPRmt is activated in skeletal muscle
during exercise as part of an adaptive response to exercise
training [54]. Here, we raise the possibility that mitochon-
drial dysfunction, UPRmt and autophagy are functionally
related to each other and promoted by a single event, that
is, the deficit in NO signalling, thus suggesting that the
association of altered mitochondrial homeostasis and
muscle phenotype/performance in NOS1-/- mice is not
coincidental.
The experiments we carried-out in myogenic precursor
cells and NOS1-/- mice during critical stages of muscle
development are consistent with an association of al-
tered mitochondrial homeostasis and muscle phenotype/performance and provide an indication of the mechanism
responsible for the impaired fibre growth resulting in a def-
icit of muscle performance. In particular, nNOSμ absence
altered mitochondrial homeostasis in myogenic precursor
cells with a decrease in the number of myonuclei per fibres
and impaired muscle development at early stages of growth.
This also suggests that fusion of myogenic precursor cells
during perinatal myogenesis is impaired. Accordingly, NO
has been shown to stimulate the ability of myogenic precur-
sor cells to become activated and fuse to each other
[5,8,85]. There is a general agreement that mitochondria
change when the myoblasts differentiate into myotubes
[27]. Also, NO maintains functional mitochondria and this
permits differentiation of myogenic precursor cells in vitro
[25]. At the signalling level, the Akt-mTOR pathway and
Akt-FoxO3-Mul-1 axis are involved in skeletal muscle
growth/wasting, autophagy and mitochondrial dysfunction
[29,31,38,46,55,58,67-69,73,74]. Of interest, Mul-1 has been
recently reported to be upregulated during muscle wasting,
possibly via an autophagic mechanism involving FoxO3
transcription factors [68]. Our data indicate the relevance
of the above signalling pathways and that they are con-
trolled by NO. We observed an inhibition of the Akt-
mTOR pathway in the absence of nNOSμ. Concomitantly,
the Akt-FoxO3-Mul-1 axis was also dysregulated. In
addition, the inhibition of the nNOS/NO/cGMP/PKG
system induced the transcriptional activity of FoxO3
and increased Mul-1 expression. These events are likely
associated with nNOSμ-dependent impairments of
muscle fibre growth.
We cannot exclude that failure of other NO-dependent
action involving, for instance, the vascular system, may
have contributed to the functional and structural defects
we observed in skeletal muscle. Extensor digitorum longus
of NOS1-/- mice revealed an altered capillary-to-fibre ra-
tio but not changes in the capillary ultrastructure or the
hemodynamics at basal conditions [86]. Noteworthy, NO
generated by sarcolemmal nNOSμ normally acts as a para-
crine signal that optimises blood flow in the working
muscle [12,87,88] and the protective vasodilating action is
impaired in the contracting muscles of NOS1-/- mice
[12,89]. In this respect, the lack of this vasodilating action
in NOS1-/- mice has been suggested to affect muscle per-
formance [71]. Results obtained in NOS1-/- mice with dif-
ferent cardiac injuries indicated a protective role of nNOS,
although an opposite effect cannot be excluded [90,91].
The deficit in exercise performance of NOS1-/- muscles
may be the consequence, at least in part, of a decreased
oxygen delivery following blood flow impairment.
Conclusions
Muscle exercise performance is a complex physiological
process that can occur by many different mechanisms
and NO has long been described to be relevant among
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NO also resides in the fact that it regulates key homeo-
static mechanisms in skeletal muscle, namely mitochon-
drial bioenergetics and network remodelling, UPRmt and
autophagy. Although NOS1-/- mice do not display the
overt features of myopathies, such as muscle degener-
ation, reactive regeneration and replacement of muscle
with fibroadipous tissue [92,93], we clearly show that al-
terations of the NO system significantly impair muscle
fibre growth, thus resulting in a deficit of muscle force
and the ability to sustain prolonged exercise. This aspect
may explain why NO deficiency contributes to muscle
impairment in degenerative disease of the muscle, such
as muscular dystrophies.
Additional files
Additional file 1: Figure S1. Mitochondrial ultrastructure and LC3
lipidation in skeletal muscles of wild-type and NOS1-/- mice. (A) TEM i
mages of subsarcolemmal mitochondria of tibialis anterior muscles. Scale
bar: 0.1 μm. (B) TEM images of intermyofibrillar mitochondria of tibialis
anterior muscles. Scale bar: 1 μm. (C) TEM images of diaphragm muscles
detecting the presence of autophagic vacuoles (arrowheads) in NOS1-/-
fibres. TEM images are representative of results obtained from at least
three different animals per experimental group. (D) Western blot analysis
of LC3 lipidation in diaphragm muscles of wild-type and NOS1-/- mice.
GAPDH was used as internal standard. The image is representative of
results obtained from at least 10 different animals per experimental
group. Analyses were performed on animals at P120.
Additional file 2: Figure S2. Weight, muscle structure and muscle
expression of ubiquitin ligases in wild-type and NOS1-/- mice. Body
(A) and visceral adipose tissue (VAT) (B) weight. Each histogram
represents the data obtained from at least three to eight different animals
per experimental group. *P <0.05, and **P <0.01 versus the respective
wild-type control. (C) Pictures of tibialis anterior, soleus, and gastrocnemius
muscles. The image is representative of at least 10 different animals per
experimental group. (D) Histological sections of tibialis anterior and
diaphragm muscles stained with H & E. The images are representative of
results obtained from at least five different animals per experimental group.
Scale bar: 100 μm. Analyses were performed on animals at P120. qPCR
analysis of mRNA levels for atrogin-1 and muRF1 in hind limb muscles at
P10 (E) and tibialis anterior muscles at P30 (F). Values are expressed as the
fold change over wild-type. Each histogram represents the data obtained
from at least five different animals per experimental group.
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